Estimating transmission pathways of COVID-19 in U.S. nursing homes

Publication date: Sep 17, 2025

Background: Pathogen transmission dynamics in nursing homes are unique due to the interactions between staff and residents. Understanding the differences in transmission rates between and among staff and residents can identify the transmission pathways that contributed most to the spread of SARS-CoV-2 in U.S. nursing homes during the pandemic. Methods: We used publicly available U.S. National Healthcare Safety Network (NHSN) surveillance data on resident and staff cases, vaccination, and resident deaths during June 2020-June 2022, to estimate SARS-CoV-2 transmission between and among residents and staff. We used a Bayesian inversion transmission model to produce the estimates. We categorized nursing homes by the number of beds, average length of stay, or community social vulnerability. We estimated weekly transmission events for three periods: pre-Delta (June 2020-March 2021), Delta (April 2021-October 2021), and Omicron (November 2021-June 2022). Results: Weekly transmission events within each nursing homes category were highest between residents in homes with >299 beds during Omicron (0.66, 95% Credible Interval (CrI): 0.13-0.93), from staff to residents in homes with average length of stay >10 weeks during pre-Delta (0.88, 95% CrI: 0.06-1.85), and between residents in homes in communities with the lowest social vulnerability index during pre-Delta (0.89, 95% CrI: 0.07-1.16). Conclusions: Transmission from staff to residents and between residents may have contributed more to SARS-CoV-2 spread in nursing homes than resident-to-staff and staff-to-staff transmission. Interventions interrupting these transmission pathways and that consider community exposures could reduce the size or duration of future outbreaks.

PDF

Concepts Keywords
Austria Copyright
Greenland Cri
Hispanic Delta
Pathogen Doi
Homes
License
Medrxiv
Nursing
Preprint
Rate
Resident
Residents
Staff
Transmission
Weeks

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Pathogen transmission
drug DRUGBANK Etoperidone
disease MESH social vulnerability
disease IDO intervention
disease IDO facility
disease MESH infection
disease MESH Death
disease IDO infection prevalence
disease MESH uncertainty
drug DRUGBANK Morpholinylmercaptobenzothiazole
disease IDO quality
disease IDO blood

Download Document

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *